arrow
J

Jingxin Fu

Dana-Farber Cancer Institute
H指数:17
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity
2026-01-210
PRE
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

早期激素受体阳性乳腺癌在抗PD-1和化疗治疗期间细胞的重编程

2025-11-280
OAAI
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

疗效、安全性及预测性生物标志物:nab-paclitaxel联合pembrolizumab治疗激素受体阳性乳腺癌的随机试点试验

2025-11-280
OAAI
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma

髓系细胞介导干扰素驱动的抗免疫疗法作用于晚期肾细胞癌

Immunity
IF26.3
2025-10-310
OAAI
Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1

SARS-CoV-2尖峰蛋白在Thermothelomyces heterothallica C1中的表达与表征

Vaccine
IF3.5
2025-09-290
OAAI
Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
2024-05-020
PRE
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

预测非小细胞肺癌免疫检查点阻断后临床结果的社区挑战

2024-02-214
OAAI
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
2023-09-2925
OA
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifi es Estrogen-Related Receptor Alpha
2023-02-0614
OAAI
A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
2022-02-152
PRE
Checkpoint blockade-induced CD8+T cell differentiation in head and neck cancer responders

检查点阻断诱导头颈癌应答者的CD8 T细胞分化

2022-01-2025
OAAI
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

治疗性增加mhc-i表达增强免疫检查点阻断

2021-02-15132
OA